CyberArk Software Ltd. - Ordinary Shares (CYBR): Price and Financial Metrics
CyberArk Software Ltd. - Ordinary Shares (CYBR)
Today's Latest Price: $121.95 USD
1.81 (1.51%)
Updated Dec 11 4:00pm
Add CYBR to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 21 in Software - Security
See all "A" rated Strong Buy stocks
CYBR Stock Summary
- With a price/earnings ratio of 82.78, CyberArk Software Ltd P/E ratio is greater than that of about 92.37% of stocks in our set with positive earnings.
- For CYBR, its debt to operating expenses ratio is greater than that reported by merely 0.39% of US equities we're observing.
- As for revenue growth, note that CYBR's revenue has grown 58.44% over the past 12 months; that beats the revenue growth of 90.9% of US companies in our set.
- Stocks that are quantitatively similar to CYBR, based on their financial statements, market capitalization, and price volatility, are DERM, LC, NICE, LEAF, and QUOT.
- Visit CYBR's SEC page to see the company's official filings. To visit the company's web site, go to www.cyberark.com.
CYBR Daily Price Range
CYBR 52-Week Price Range
CYBR Stock Price Chart More Charts
CYBR Price/Volume Stats
| Current price | $121.95 | 52-week high | $148.74 |
| Prev. close | $120.14 | 52-week low | $65.90 |
| Day low | $119.13 | Volume | 424,348 |
| Day high | $121.99 | Avg. volume | 848,805 |
| 50-day MA | $110.36 | Dividend yield | N/A |
| 200-day MA | $118.82 | Market Cap | 4.60B |
CyberArk Software Ltd. - Ordinary Shares (CYBR) Company Bio
Cyberark Software develops, markets, and sells software-based IT security solutions that protect organizations from cyber attacks in the United States and internationally. The company was founded in 1999 and is based in Petach Tikva, Israel.
Top Stories View All
Is Now the Time to Buy Shares of Aurora Cannabis (ACB)?
The 6 Rookie Mistakes Options Traders Should Avoid
[Just Released] 2020 Stock Market Outlook
3 Things Investors Need To Know About The Blowout Jobs Report
Why Investors Should be Bullish About GW Pharmaceuticals (GWPH)
View All Top Stories
Loading social stream, please wait...